Autors:

CiteWeb id: 20090000051

CiteWeb score: 6123

DOI: 10.1056/NEJMoa040720

Background Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prostate cancer, but it does not improve survival. We compared such treatment with docetaxel plus prednisone in men with this disease. Methods From March 2000 through June 2002, 1006 men with metastatic hormone-refractory prostate cancer received 5 mg of prednisone twice daily and were randomly assigned to receive 12 mg of mitoxantrone per square meter of body-surface area every three weeks, 75 mg of docetaxel per square meter every three weeks, or 30 mg of docetaxel per square meter weekly for five of every six weeks. The primary end point was overall survival. Secondary end points were pain, prostate-specific antigen (PSA) levels, and the quality of life. All statistical comparisons were against mitoxantrone. Results As compared with the men in the mitoxantrone group, men in the group given docetaxel every three weeks had a hazard ratio for death of 0.76 (95 percent confidence i...

The publication "Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer" is placed in the Top 10000 of the best publications in CiteWeb. Also in the category Medicine it is included to the Top 1000. Additionally, the publicaiton "Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer" is placed in the Top 100 among other scientific works published in 2009.
Links to full text of the publication: